Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.

Pharmaceutical firm Eli Lilly is in line for an exit from US-based liver disease drug developer Terns Pharmaceuticals, which has filed for a $100m initial public offering. Terns is working on small-molecule drugs to treat chronic liver diseases including non-alcoholic steatohepatitis (NASH). Part of the IPO proceeds will support the completion of a phase 2a…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.